tradingkey.logo

Canada approves Ozempic to reduce risk of diabetic kidney disease progression

ReutersAug 19, 2025 11:07 AM

- Canada's health regulator has approved Novo Nordisk's NOVOb.CO diabetes drug, Ozempic, for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease, the Danish drugmaker said on Tuesday.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI